Skip to contentN
Nika Pharmaceuticals, Inc
N
NIKANika Pharmaceuticals, Inc Q1 2024 · 10-Q
Revenue—
Net Income-$65.99K-$65.99KN/M vs Q1 2023 EPS Diluted$0.00$0.00— vs Q1 2023 Operating Income-$65,988N/M Operating Cash Flow-$150,007N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nika Pharmaceuticals, Inc · CIK 1145604 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed May 28, 2024 · 58 d after period end